# A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy

> **NCT00109317** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 686 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Raptiva (efalizumab)

## Key facts

- **NCT ID:** NCT00109317
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** —
- **Final completion:** 2003-02
- **Target enrollment:** 686 (ACTUAL)
- **Last updated:** 2013-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00109317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00109317, "A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00109317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*